Page last updated: 2024-09-04

torcetrapib and Coronary Artery Disease

torcetrapib has been researched along with Coronary Artery Disease in 16 studies

Research

Studies (16)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	13 (81.25)	29.6817
2010's	3 (18.75)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akhlaghi, F; Mohammadpour, AH	1
Bots, ML; Doevendans, PA; Grobbee, DE; Jukema, JW; Kastelein, JJ; Kuivenhoven, JA; Regieli, JJ; van der Graaf, Y; Zwinderman, AH	1
Brennan, DM; Nicholls, SJ; Nissen, SE; Tardif, JC; Tuzcu, EM	1
Olsson, AG	1
Buckley, BM; Burgess, T; Capponi, AM; Kallend, D; Kastelein, JJ; Niesor, EJ; Stein, EA; Steiner, G; Stroes, ES	1
Barter, P	1
Böhm, M; Laufs, U; Pöss, J	1
Brudaşcă, I; Cucuianu, M	1
Doggrell, SA	1
Avorn, J	1
Shear, CL	1
Lavie, CJ; Milani, RV	1
Bachinsky, WB; Duggan, WT; Lasala, GP; Nicholls, SJ; Nissen, SE; Revkin, JH; Ruzyllo, W; Shear, CL; Tardif, JC; Tuzcu, EM	1
Tall, AR	1
Asztalos, BF; Schaefer, EJ	1
Kastelein, JJ	1

Reviews

6 review(s) available for torcetrapib and Coronary Artery Disease

Article	Year
Is high HDL cholesterol always good? Annals of medicine, 2009, Volume: 41, Issue:1 Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Humans; Quinolines; Risk; Treatment Outcome	2009
[HDL and CETP in atherogenesis]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:5 Topics: Amides; Anticholesteremic Agents; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Esters; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Nicotinic Acids; Oxazolidinones; Quinolines; Randomized Controlled Trials as Topic; Sulfhydryl Compounds; Treatment Outcome	2010
Controversy on high density lipoprotein raising therapy. Romanian journal of internal medicine = Revue roumaine de medecine interne, 2010, Volume: 48, Issue:2 Topics: Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Artery Disease; Humans; Hypolipoproteinemias; Lipid Metabolism; Lipoproteins, HDL; Mice; Quinolines; Rabbits; Rats; Risk Factors; Treatment Failure	2010
Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein - a new approach to coronary artery disease. Expert opinion on investigational drugs, 2004, Volume: 13, Issue:10 Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid; Coronary Artery Disease; Glycoproteins; Humans; Quinolines	2004
Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. The American journal of cardiology, 2007, Dec-03, Volume: 100, Issue:11 A Topics: Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Humans; Quinolines; Risk Factors	2007
Refocusing on use of cholesteryl ester transfer protein inhibitors. The American journal of cardiology, 2007, Dec-03, Volume: 100, Issue:11 A Topics: Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Humans; Quinolines	2007

Trials

3 trial(s) available for torcetrapib and Coronary Artery Disease

Article	Year
Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosi Circulation, 2008, Dec-09, Volume: 118, Issue:24 Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Disease Progression; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Middle Aged; Potassium; Pyrroles; Quinolines; Sodium; Ultrasonography	2008
Safety and tolerability of dalcetrapib. The American journal of cardiology, 2009, Jul-01, Volume: 104, Issue:1 Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Esters; Female; Humans; Incidence; Male; Middle Aged; Quinolines; Risk Assessment; Risk Factors; Sulfhydryl Compounds	2009
Effect of torcetrapib on the progression of coronary atherosclerosis. The New England journal of medicine, 2007, Mar-29, Volume: 356, Issue:13 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Ultrasonography, Interventional	2007

Other Studies

7 other study(ies) available for torcetrapib and Coronary Artery Disease

Article	Year
Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clinical pharmacokinetics, 2013, Volume: 52, Issue:8 Topics: Amides; Animals; Anticholesteremic Agents; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Esters; Humans; Oxazolidinones; Quinolines; Sulfhydryl Compounds	2013
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. European heart journal, 2008, Volume: 29, Issue:22 Topics: Alleles; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Genotype; Humans; Male; Pharmacogenetics; Polymorphism, Genetic; Pravastatin; Predictive Value of Tests; Quinolines; Randomized Controlled Trials as Topic	2008
Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. The American journal of cardiology, 2009, Nov-16, Volume: 104, Issue:10 Suppl Topics: Animals; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Early Termination of Clinical Trials; Genetic Predisposition to Disease; Humans; Quinolines; Randomized Controlled Trials as Topic	2009
Torcetrapib and atorvastatin--should marketing drive the research agenda? The New England journal of medicine, 2005, Jun-23, Volume: 352, Issue:25 Topics: Anticholesteremic Agents; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Drug Approval; Drug Combinations; Drug Industry; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Marketing; Molecular Structure; Pyrroles; Quinolines; Research Design; United States; United States Food and Drug Administration	2005
Torcetrapib and atorvastatin. The New England journal of medicine, 2005, Oct-06, Volume: 353, Issue:14 Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Combinations; Drug Industry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines	2005
Cholesteryl ester transfer protein inhibition: the next frontier in combating coronary artery disease? Journal of the American College of Cardiology, 2006, Nov-07, Volume: 48, Issue:9 Topics: Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Humans; Quinolines	2006
CETP inhibitors to increase HDL cholesterol levels. The New England journal of medicine, 2007, Mar-29, Volume: 356, Issue:13 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Pyrroles; Quinolines	2007